Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 4/20 | 0.38 |
| ▸ | BACE1 | P56817 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.36 |
| ▸ | FAP | Q12884 | 2/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | PITRM1 | Q5JRX3 | 1/20 | 0.34 |
| ▸ | PIK3C3 | Q8NEB9 | 3/20 | 0.33 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.33 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17386672 | 0.84 | LMNA (0.40) | DPP4BACE1LMNAHSD17B10CYP2C19 | |
| SCHEMBL5808993 | 0.82 | DPP4 (0.42) | DPP4LMNAHSD17B10CYP2C19DPP8 | |
| SCHEMBL4765068 | 0.77 | DPP4 (0.38) | DPP4LMNAHSD17B10CYP2C19DPP8 | |
| SCHEMBL22468655 | 0.74 | NAMPT (0.39) | DPP4LMNADPP8DPP9FAP | |
| SCHEMBL7654045 | 0.74 | NUDT1 (0.37) | DPP4PIK3C3NUDT1 | |
| SCHEMBL4607696 | 0.74 | NUDT1 (0.37) | DPP4PIK3C3NUDT1 | |
| SCHEMBL5378515 | 0.74 | NUDT1 (0.37) | DPP4PIK3C3NUDT1 | |
| SCHEMBL27736032 | 0.71 | DPP4 (0.38) | DPP4LMNAHSD17B10CYP2C19DPP8 | |
| SCHEMBL29785152 | 0.71 | DPP4 (0.38) | DPP4LMNAHSD17B10CYP2C19DPP8 | |
| SCHEMBL27715252 | 0.71 | DPP4 (0.38) | DPP4LMNAHSD17B10CYP2C19DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207156-B2 | Substituted pyrazoline compounds, their preparation and use as medicaments | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-06-26 | — | — | US | disclosed |
| EP-1946777-A1 | Substituted pyrazoline for preventing weight gain | Laboratorios del Dr. Esteve S.A. (ES) | 2008-07-23 | — | — | EP | disclosed |
| US-20070021398-A1 | Substituted Pyrazoline Compounds, their Preparation and Use as Medicaments | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021398-A1 | Substituted Pyrazoline Compounds, their Preparation and Use as Medicaments | PIR, SYMPK, P2RX5 | DPP4 38/4885BACE1 3722/4885LMNA 1928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.